References


  1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin, 2013;63:11-30.

  2. Howlader N, Noone A, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2009.

  3. Shahinian V, Kuo Y, Gilbert S. Reimbursement policy and androgen-deprivation therapy for prostate cancer. N Engl J Med 2010:363:1822-1832.

  4. Diamond T, Higano C, Smith M, et al. Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies. Cancer 2004;100:892-899.

  5. Elliott M, Wilcox A, Carnes M, et al. Androgen deprivation in veterans with prostate cancer: implications for skeletal health. Ann Pharmacother 2006;40:2107-2014.

  6. Conde F, Sarna L, Oka R, et al. Age, body mass index, and serum prostate-specific antigen correlate with bone loss in men with prostate cancer not receiving androgen deprivation therapy. Urology 2004;64:335-340.

  7. Saylor P, Lee R, Smith M. Emerging therapies to prevent skeletal morbidity in men with prostate cancer. J Clin Oncol 2011;29:3705-3714.

  8. VanderWalde A, Hurria A. Aging and osteoporosis in breast and prostate cancer. Ca Cancer J Clin 2011;61:139-156..

  9. Kaufman J, Johnell O, Abadie E, et al. Background for the studies on the treatment of male osteoporosis: state of the art. Ann Rheum Dis 2000;59:765-772.

  10. Smith M, McGovern F, Zietman A, et al. Pamidronate to prevent bone loss during androgen deprivation therapy for prostate cancer. N Engl J Med 2001;345:948-955.

  11. Stoch S, Parker R, Chen L, et al. Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists. J Clin Endocrinol Metab 2001;86:2787-2791.

  12. Berruti A, Dogliotti L, Terrone C, et al. Changes in bone mineral density, lean body mass and fat content as measured by dual energy X-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. J Urol 2002;167:2361-2367.

  13. Greenspan S, Coates P, Sereika S, et al. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J Clin Endocrinol Metab 2005;90:6410-6417.

  14. Shahinian V, Kuo Y, Freeman J, et al. Risk of fracture after androgen deprivation for prostate cancer. 
N Engl J Med 2005;352:154-164

  15. Smith MR, Egerdie B, Hernández Toriz N, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009;361:745-755.

  16. Smith MR, Morton RA, Barnette KG, et al. Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer. J Urol 2010;184:1316-1321. 

  17. Campion J, Maricic M. Osteoporosis in men. Am Fam Physician 2003;67:1521-1526. 

  18. Ryan C, Petkov V, and Adler R. Osteoporosis in men: the value of laboratory testing. Osteoporos Int 2011; 22(6):1845-1853.

  19. WHO Study Group on Assessment of Fracture Risk and its Application to Screening for Postmenopausal Osteoporosis. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Geneva: World Health Organization, 1994.

  20. Faulkner K. Bone densitometry: choosing the proper skeletal site to measure. J Clin Densitom 1998; 1:279-285.

  21. National Osteoporosis Foundation. Clinician’s Guide to Prevention and Treatment of Osteoporosis. Washington,DC: National Osteoporosis Foundation; 2010.

  22. Gralow J, Biermann J, Farooki A, et al. NCCN Task Force Report: Bone Health in Cancer Care. J Natl Compr Canc Netw 2009;7 Suppl 3:S1-S32. 

  23. Higano C. Bone loss and the evolving role of bisphosphonate therapy in prostate cancer. Urol Oncol 2003;21:392-398.

  24. Orwoll E, Ettinger M, Weiss S, et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med 2000;343:604-610.

  25. Boonen S, Reginster J, Kaufman J, et al. Fracture risk and zoledronic acid therapy in men with osteoporosis. N Engl J Med 2012;367:1714-1723.

  26. Saad F, Gleason D, Murray R, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004 Jun 2;96:879-882.

  27. Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomized, double-blind study. Lancet 2011;377(9768):813-822.

  28. Scher H, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012;367:1187-1197.

  29. Logothetis C, Basch E, Molina A, et al. Effect 
of abiraterone acetate and prednisone 
compared with placebo and prednisone 
on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. Lancet Oncol 2012;13:1210-1217.

  30. Parker C, Nilsson S, Heinrich D, et al. Updated analysis of the phase III, double-blind, randomized, multinational study of radium-223 chloride in castration-resistant prostate cancer (CRPC) patients with bone metastases (ALSYMPCA). J Clin Oncol 2012 ASCO Annual Meeting Proceedings (Post-Meeting Edition) 2012 Jun 20 supplement: LBA4512.

  31. Vogelzang N, Parker C, Nilsson S, et al. Updated analysis of radium-223 dichloride (Ra-223) 
impact on skeletal-related events (SRE) in 
patients with castration-resistant prostate cancer (CRCP) and bone metastases from the phase III randomized trial (ALSYMPCA). J Clin Oncol 2013;31 abstr 11.

  32. Smith D, Smith M, Sweeney C, et al. Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J Clin Oncol 2013;31:412-419.


From the June 01, 2013 Issue of Renal and Urology News